179 related articles for article (PubMed ID: 28203756)
1. Non-canonical roles of Bcl-2 and Bcl-xL proteins: relevance of BH4 domain.
Gabellini C; Trisciuoglio D; Del Bufalo D
Carcinogenesis; 2017 Jun; 38(6):579-587. PubMed ID: 28203756
[TBL] [Abstract][Full Text] [Related]
2. BH4 domain of Bcl-2 as a novel target for cancer therapy.
Liu Z; Wild C; Ding Y; Ye N; Chen H; Wold EA; Zhou J
Drug Discov Today; 2016 Jun; 21(6):989-96. PubMed ID: 26631752
[TBL] [Abstract][Full Text] [Related]
3. Diva, a Bcl-2 homologue that binds directly to Apaf-1 and induces BH3-independent cell death.
Inohara N; Gourley TS; Carrio R; Muñiz M; Merino J; Garcia I; Koseki T; Hu Y; Chen S; Núñez G
J Biol Chem; 1998 Dec; 273(49):32479-86. PubMed ID: 9829980
[TBL] [Abstract][Full Text] [Related]
4. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4.
Huang DC; Adams JM; Cory S
EMBO J; 1998 Feb; 17(4):1029-39. PubMed ID: 9463381
[TBL] [Abstract][Full Text] [Related]
5. CYD0281, a Bcl-2 BH4 domain antagonist, inhibits tumor angiogenesis and breast cancer tumor growth.
Lin Y; Zhao Y; Chen M; Li Z; Liu Q; Chen J; Ding Y; Ding C; Ding Y; Qi C; Zheng L; Li J; Zhang R; Zhou J; Wang L; Zhang QQ
BMC Cancer; 2023 May; 23(1):479. PubMed ID: 37237269
[TBL] [Abstract][Full Text] [Related]
6. A novel Bcl-x splice product, Bcl-xAK, triggers apoptosis in human melanoma cells without BH3 domain.
Hossini AM; Geilen CC; Fecker LF; Daniel PT; Eberle J
Oncogene; 2006 Apr; 25(15):2160-9. PubMed ID: 16288206
[TBL] [Abstract][Full Text] [Related]
7. Proteins of the bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities.
Chan SL; Yu VC
Clin Exp Pharmacol Physiol; 2004 Mar; 31(3):119-28. PubMed ID: 15008953
[TBL] [Abstract][Full Text] [Related]
8. The Bcl-2 family: structures, interactions and targets for drug discovery.
Kvansakul M; Hinds MG
Apoptosis; 2015 Feb; 20(2):136-50. PubMed ID: 25398535
[TBL] [Abstract][Full Text] [Related]
9. Functional dissection of Bfl-1, a Bcl-2 homolog: anti-apoptosis, oncogene-cooperation and cell proliferation activities.
D'Sa-Eipper C; Chinnadurai G
Oncogene; 1998 Jun; 16(24):3105-14. PubMed ID: 9671389
[TBL] [Abstract][Full Text] [Related]
10. Expression and function of a proapoptotic Bcl-2 family member Bcl-XL/Bcl-2-associated death promoter (BAD) in rat ovary.
Kaipia A; Hsu SY; Hsueh AJ
Endocrinology; 1997 Dec; 138(12):5497-504. PubMed ID: 9389536
[TBL] [Abstract][Full Text] [Related]
11. Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death.
Reed JC; Zha H; Aime-Sempe C; Takayama S; Wang HG
Adv Exp Med Biol; 1996; 406():99-112. PubMed ID: 8910675
[TBL] [Abstract][Full Text] [Related]
12. The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond.
Monaco G; Vervliet T; Akl H; Bultynck G
Cell Mol Life Sci; 2013 Apr; 70(7):1171-83. PubMed ID: 22955373
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis induction by Bcl-2 proteins independent of the BH3 domain.
Hossini AM; Eberle J
Biochem Pharmacol; 2008 Dec; 76(11):1612-9. PubMed ID: 18778689
[TBL] [Abstract][Full Text] [Related]
14. Discovery and identification of a novel small molecule BCL-2 inhibitor that binds to the BH4 domain.
Zhou JY; Yang RR; Chang J; Song J; Fan ZS; Zhang YH; Lu CH; Jiang HL; Zheng MY; Zhang SL
Acta Pharmacol Sin; 2023 Feb; 44(2):475-485. PubMed ID: 35918411
[TBL] [Abstract][Full Text] [Related]
15. Mtd, a novel Bcl-2 family member activates apoptosis in the absence of heterodimerization with Bcl-2 and Bcl-XL.
Inohara N; Ekhterae D; Garcia I; Carrio R; Merino J; Merry A; Chen S; Núñez G
J Biol Chem; 1998 Apr; 273(15):8705-10. PubMed ID: 9535847
[TBL] [Abstract][Full Text] [Related]
16. Comparative genomics: the evolutionary history of the Bcl-2 family.
Lanave C; Santamaria M; Saccone C
Gene; 2004 May; 333():71-9. PubMed ID: 15177682
[TBL] [Abstract][Full Text] [Related]
17. BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition.
Gabellini C; De Luca T; Trisciuoglio D; Desideri M; Di Martile M; Passeri D; Candiloro A; Biffoni M; Rizzo MG; Orlandi A; Del Bufalo D
Carcinogenesis; 2013 Nov; 34(11):2558-67. PubMed ID: 23836782
[TBL] [Abstract][Full Text] [Related]
18. Ryanodine receptors are targeted by anti-apoptotic Bcl-XL involving its BH4 domain and Lys87 from its BH3 domain.
Vervliet T; Lemmens I; Vandermarliere E; Decrock E; Ivanova H; Monaco G; Sorrentino V; Nadif Kasri N; Missiaen L; Martens L; De Smedt H; Leybaert L; Parys JB; Tavernier J; Bultynck G
Sci Rep; 2015 Apr; 5():9641. PubMed ID: 25872771
[TBL] [Abstract][Full Text] [Related]
19. Cancer cell death strategies by targeting Bcl-2's BH4 domain.
de Ridder I; Kerkhofs M; Veettil SP; Dehaen W; Bultynck G
Biochim Biophys Acta Mol Cell Res; 2021 Apr; 1868(5):118983. PubMed ID: 33549704
[TBL] [Abstract][Full Text] [Related]
20. Ectopic expression of Bcl-XL or Ku70 protects human colon cancer cells (SW480) against curcumin-induced apoptosis while their down-regulation potentiates it.
Rashmi R; Kumar S; Karunagaran D
Carcinogenesis; 2004 Oct; 25(10):1867-77. PubMed ID: 15205359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
